PRAME antibody (AA 151-250) (Cy3)

Catalog No. ABIN721558

This Rabbit Polyclonal antibody specifically detects PRAME in FACS, IF (cc) and IF (p). It exhibits reactivity toward Human and Mouse.

Quick Overview for PRAME antibody (AA 151-250) (Cy3) (ABIN721558)

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PRAME antibody is conjugated to Cy3

Application: Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Product Details anti-PRAME Antibody (Cy3)

Binding Specificity: AA 151-250

Cross-Reactivity: Human, Mouse

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human PRAME

Isotype: IgG

Application Details

Application Notes: FCM 1:20-100
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for PRAME

Target: PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))

Alternative Name: PRAME

Background:

Synonyms: MAPE, OIP4, CT130, OIP-4, Melanoma antigen preferentially expressed in tumors, Opa-interacting protein 4, Preferentially expressed antigen of melanoma, PRAME

Background: Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. Prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.

Gene ID: 23532

UniProt: P78395

Pathways: Retinoic Acid Receptor Signaling Pathway, Nuclear Hormone Receptor Binding